Cullinan Therapeutics, Inc. in brief
Cullinan Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Cambridge, Massachusetts, USA. It employs about 109 people and Nadim Ahmed is its chief executive. Its shares trade under the symbol CGEM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Cullinan Therapeutics, Inc.
CLN-978 is a CD19xCD3 bispecific T cell engager that we are developing for autoimmune diseases. In the Phase 1 OUTRACE Program, CLN-978 is being evaluated in patients with systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s disease. The OUTRACE SLE Study is an ongoing global Phase 1 clinical trial in patients with moderate to severe SLE. The OUTRACE RA Study is a Phase 1 clinical trial in patients with active, difficult-to-treat RA, which is ongoing in Europe. We plan to share initial clinical data in SLE and RA in the second quarter of 2026 and repeat dosing data in RA in the third quarter of 2026. The OUTRACE SjD Study is an ongoing global Phase 1 clinical trial in patients with active, moderate to severe Sjögren’s disease. We plan to share initial clinical data in Sjögren’s disease in the fourth quarter of 2026.
From the company's annual report filed with the US SEC: read the report
Cullinan Therapeutics, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- ✎Renamed Cullinan Management, Inc.Formerly Cullinan Oncology, LLC.
- 🔔Initial public offering as Cullinan Management, Inc.Final prospectus filed with the SEC on 11 January 2021; shares registered for exchange trading on 6 January 2021.
- ✎Renamed Cullinan Oncology, Inc.Formerly Cullinan Management, Inc..
- 2024
- ✎Renamed Cullinan Therapeutics, Inc.Formerly Cullinan Oncology, Inc..
Events of Cullinan Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -53.8%
- Liabilities / assets
- 8.8%
- R&D / revenue
- 304.9%
- Profit per employee
- $-2.0 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-242M | $-220M | — |
| Dec 2024 | — | — | $-197M | $-167M | — |
| Dec 2023 | — | — | $-191M | $-153M | — |
| Dec 2022 | — | — | $145M | $111M | — |
| Dec 2021 | $19M | — | $-68M | $-66M | -346.2% |
| Dec 2020 | — | — | $-60M | $-52M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-176M | $0M | $-176M | — | — |
| Dec 2024 | $-145M | $0M | $-145M | — | — |
| Dec 2023 | $-134M | $0M | $-134M | $-3.69 | — |
| Dec 2022 | $-127M | $1M | $-128M | $2.38 | — |
| Dec 2021 | $-43M | $0M | $-43M | $-1.52 | — |
| Dec 2020 | $-30M | $0M | $-30M | $-2.60 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-49M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Nov 9, 20268-KCurrent reportRegulation FD disclosure · Other events
- Nov 4, 20268-KCurrent reportRegulation FD disclosure · Other events
- Oct 2, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 24, 20268-KCurrent reportRegulation FD disclosure · Other events
- Sep 14, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 13, 20268-KCurrent reportRegulation FD disclosure · Other events
- Aug 6, 202610-QQuarterly report · period to Jun 2026
- Aug 6, 20268-KCurrent reportResults of operations
- Jun 16, 20268-KCurrent reportShareholder vote
- Jun 10, 20268-KCurrent reportRegulation FD disclosure · Other events
Official filings of Cullinan Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-242 M
- Net income
- $-220 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $448 M
- Total liabilities
- $40 M
- Total equity
- $409 M
As of December-2025
Top 100 institutional investors in Cullinan Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | MPM Bioimpact LLC | 9,721,081 | -10,260 (-0.11%) | 14.97% | $149 M | Nov 16, 2026 |
| 2 | Lynx1 Capital Management LP | 8,963,500 | 0 (0.00%) | 13.81% | $138 M | Nov 16, 2026 |
| 3 | BVF Inc/il | 5,750,683 | 0 (0.00%) | 8.86% | $88 M | Nov 16, 2026 |
| 4 | BlackRock, Inc. | 5,319,313 | +86,547 (+1.65%) | 8.19% | $82 M | Nov 13, 2026 |
| 5 | Price T Rowe Associates Inc /MD/ | 4,091,640 | +265,690 (+6.94%) | 6.30% | $63 M | Nov 16, 2026 |
| 6 | Kynam Capital Management, LP | 3,114,132 | 0 (0.00%) | 4.80% | $48 M | Nov 16, 2026 |
| 7 | Vanguard Capital Management LLC | 2,641,522 | +27,456 (+1.05%) | 4.07% | $41 M | Nov 13, 2026 |
| 8 | State Street Corp | 2,604,105 | -1,064,522 (-29.02%) | 4.01% | $40 M | Nov 12, 2026 |
| 9 | RTW Investments, LP | 2,364,347 | 0 (0.00%) | 3.64% | $36 M | Nov 16, 2026 |
| 10 | Siren, L.L.C. | 1,793,410 | -100,000 (-5.28%) | 2.76% | $28 M | Nov 12, 2026 |
| 11 | Geode Capital Management, LLC | 1,448,600 | -98,709 (-6.38%) | 2.23% | $22 M | Nov 6, 2026 |
| 12 | Blue Owl Capital Holdings LP | 1,399,899 | -139,865 (-9.08%) | 2.16% | $21 M | Nov 13, 2026 |
| 13 | Venrock Adviser, LLC | 1,379,965 | 0 (0.00%) | 2.13% | $21 M | Nov 16, 2026 |
| 14 | Dimensional Fund Advisors LP | 1,084,765 | +38,071 (+3.64%) | 1.67% | $17 M | Nov 4, 2026 |
| 15 | Goldman Sachs Group Inc | 988,963 | -12,635 (-1.26%) | 1.52% | $15 M | Nov 16, 2026 |
| 16 | Elmind Capital, LP | 962,792 | +272,792 (+39.54%) | 1.48% | $15 M | Nov 16, 2026 |
| 17 | Boothbay Fund Management, LLC | 953,126 | -129,485 (-11.96%) | 1.47% | $15 M | Nov 16, 2026 |
| 18 | Affinity Asset Advisors, LLC | 875,760 | 0 (0.00%) | 1.35% | $13 M | Nov 13, 2026 |
| 19 | Fisher Asset Management, LLC | 800,961 | +764,963 (+2125.02%) | 1.23% | $12 M | Nov 6, 2026 |
| 20 | Boone Capital Management LLC | 690,814 | -13,628 (-1.93%) | 1.06% | $11 M | Nov 16, 2026 |
| 21 | Morgan Stanley | 644,639 | +15,604 (+2.48%) | 0.99% | $10 M | Nov 13, 2026 |
| 22 | Vanguard Portfolio Management LLC | 643,491 | -95,250 (-12.89%) | 0.99% | $10 M | Nov 13, 2026 |
| 23 | Twin Focus Capital Partners, LLC | 595,489 | 0 (0.00%) | 0.92% | $9 M | Nov 13, 2026 |
| 24 | Northern Trust Corp | 558,159 | -12,921 (-2.26%) | 0.86% | $9 M | Nov 16, 2026 |
| 25 | Charles Schwab Investment Management Inc | 506,077 | +42,043 (+9.06%) | 0.78% | $8 M | Nov 16, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | AQR Capital Management LLC | 498,566 | -82,772 (-14.24%) | 0.77% | $8 M | Nov 16, 2026 |
| 27 | Boxer Capital Management, LLC | 450,000 | New | 0.69% | $7 M | Nov 16, 2026 |
| 28 | Bank Of America Corp /de/ | 415,972 | -94,353 (-18.49%) | 0.64% | $6 M | Nov 16, 2026 |
| 29 | TCG Crossover Management, LLC | 406,786 | 0 (0.00%) | 0.63% | $6 M | Nov 16, 2026 |
| 30 | Deutsche Bank AG\ | 377,837 | -5,003 (-1.31%) | 0.58% | $6 M | Nov 6, 2026 |
| 31 | Vanguard Fiduciary Trust Co | 376,124 | +12,988 (+3.58%) | 0.58% | $6 M | Nov 13, 2026 |
| 32 | FMR LLC | 336,451 | +96,336 (+40.12%) | 0.52% | $5 M | Nov 10, 2026 |
| 33 | Great Point Partners LLC | 300,000 | 0 (0.00%) | 0.46% | $5 M | Nov 16, 2026 |
| 34 | Renaissance Technologies LLC | 290,011 | -36,800 (-11.26%) | 0.45% | $4 M | Nov 12, 2026 |
| 35 | Connor, Clark & Lunn Investment Management Ltd. | 286,096 | -6,404 (-2.19%) | 0.44% | $4 M | Nov 10, 2026 |
| 36 | Invesco Ltd. | 283,144 | +139,592 (+97.24%) | 0.44% | $4 M | Nov 12, 2026 |
| 37 | Jpmorgan Chase & Co | 273,316 | -9,315 (-3.30%) | 0.42% | $4 M | Nov 12, 2026 |
| 38 | Wellington Management Group LLP | 262,713 | +97,997 (+59.49%) | 0.40% | $4 M | Nov 16, 2026 |
| 39 | Bleichroeder LP | 250,000 | 0 (0.00%) | 0.39% | $4 M | Nov 13, 2026 |
| 40 | UBS Group AG | 229,203 | -19,424 (-7.81%) | 0.35% | $4 M | Nov 10, 2026 |
| 41 | Two Sigma Investments, LP | 219,719 | -52,862 (-19.39%) | 0.34% | $3 M | Nov 16, 2026 |
| 42 | Trexquant Investment LP | 209,314 | +57,151 (+37.56%) | 0.32% | $3 M | Nov 16, 2026 |
| 43 | Apis Capital Advisors, LLC | 192,000 | +112,000 (+140.00%) | 0.30% | $3 M | Nov 13, 2026 |
| 44 | Moore Capital Management, LP | 181,306 | -8,640 (-4.55%) | 0.28% | $3 M | Nov 16, 2026 |
| 45 | Barclays PLC | 177,595 | +33,650 (+23.38%) | 0.27% | $3 M | Nov 6, 2026 |
| 46 | HighVista Strategies LLC | 173,895 | New | 0.27% | $3 M | Nov 13, 2026 |
| 47 | Bank of New York Mellon Corp | 173,387 | +2,356 (+1.38%) | 0.27% | $3 M | Nov 5, 2026 |
| 48 | Nuveen, LLC | 167,014 | -304,933 (-64.61%) | 0.26% | $3 M | Nov 10, 2026 |
| 49 | American Century Companies Inc | 158,532 | +2,215 (+1.42%) | 0.24% | $2 M | Nov 12, 2026 |
| 50 | Susquehanna Portfolio Strategies, LLC | 121,561 | -112,281 (-48.02%) | 0.19% | $2 M | Nov 16, 2026 |
| 51 | Quantinno Capital Management LP | 121,425 | +11,549 (+10.51%) | 0.19% | $2 M | Nov 13, 2026 |
| 52 | PFM Health Sciences, LP | 104,715 | -87,727 (-45.59%) | 0.16% | $2 M | Nov 16, 2026 |
| 53 | Informed Momentum Co LLC | 104,075 | New | 0.16% | $2 M | Nov 16, 2026 |
| 54 | Raymond James Financial Inc | 98,240 | New | 0.15% | $2 M | Nov 12, 2026 |
| 55 | Creative Planning | 96,738 | +10,280 (+11.89%) | 0.15% | $1 M | Nov 2, 2026 |
| 56 | Woodline Partners LP | 96,572 | New | 0.15% | $1 M | Nov 16, 2026 |
| 57 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 95,456 | +11,278 (+13.40%) | 0.15% | $1 M | Nov 16, 2026 |
| 58 | Knott David M Jr | 95,369 | +26,187 (+37.85%) | 0.15% | $1 M | Nov 12, 2026 |
| 59 | Manufacturers Life Insurance Company, The | 83,507 | +6,796 (+8.86%) | 0.13% | $1 M | Nov 13, 2026 |
| 60 | Rhumbline Advisers | 82,612 | +3,682 (+4.66%) | 0.13% | $1 M | Nov 10, 2026 |
| 61 | Weiss Asset Management LP | 81,762 | New | 0.13% | $1 M | Nov 16, 2026 |
| 62 | TD Asset Management Inc | 80,628 | 0 (0.00%) | 0.12% | $1 M | Nov 13, 2026 |
| 63 | Longaeva Partners L.P. | 79,751 | +14,966 (+23.10%) | 0.12% | $1 M | Nov 16, 2026 |
| 64 | Swiss National Bank | 77,600 | +1,600 (+2.11%) | 0.12% | $1 M | Nov 12, 2026 |
| 65 | Ellsworth Advisors, LLC | 74,856 | New | 0.12% | $1 M | Oct 15, 2026 |
| 66 | Susquehanna International Group, LLP | 71,351 | +45,261 (+173.48%) | 0.11% | $1 M | Nov 16, 2026 |
| 67 | Mariner, LLC | 68,182 | -6,091 (-8.20%) | 0.10% | $1 M | Nov 12, 2026 |
| 68 | Tidal Investments LLC | 67,125 | +4,299 (+6.84%) | 0.10% | $1 M | Nov 13, 2026 |
| 69 | Tema Etfs LLC | 67,125 | +4,299 (+6.84%) | 0.10% | $1 M | Oct 16, 2026 |
| 70 | Algert Global LLC | 64,021 | +27,170 (+73.73%) | 0.10% | $1 M | Nov 17, 2026 |
| 71 | Alliancebernstein L.P. | 63,460 | -11,790 (-15.67%) | 0.10% | $1 M | Nov 16, 2026 |
| 72 | Martingale Asset Management L P | 61,938 | 0 (0.00%) | 0.10% | $1 M | Nov 12, 2026 |
| 73 | Kennedy Capital Management LLC | 58,446 | +5,436 (+10.25%) | 0.09% | $1 M | Nov 13, 2026 |
| 74 | Corient Private Wealth LP | 53,909 | -968 (-1.76%) | 0.08% | $1 M | Nov 16, 2026 |
| 75 | Rafferty Asset Management, LLC | 53,230 | -12,862 (-19.46%) | 0.08% | $1 M | Nov 13, 2026 |
| 76 | State Of Wisconsin Investment Board | 53,055 | +33,005 (+164.61%) | 0.08% | $1 M | Nov 16, 2026 |
| 77 | Citadel Advisors LLC | 52,838 | -344,646 (-86.71%) | 0.08% | $1 M | Nov 16, 2026 |
| 78 | Franklin Templeton Inc | 42,541 | +196 (+0.46%) | 0.07% | $1 M | Nov 12, 2026 |
| 79 | Engineers Gate Manager LP | 42,384 | -110,666 (-72.31%) | 0.07% | $1 M | Nov 16, 2026 |
| 80 | California State Teachers Retirement System | 40,253 | 0 (0.00%) | 0.06% | $1 M | Nov 13, 2026 |
| 81 | Vanguard Global Advisers, LLC | 38,824 | +2,047 (+5.57%) | 0.06% | $1 M | Nov 13, 2026 |
| 82 | Massachusetts Financial Services Co /ma/ | 38,643 | +6,930 (+21.85%) | 0.06% | $1 M | Nov 12, 2026 |
| 83 | HRT Financial LP | 38,156 | New | 0.06% | $1 M | Nov 13, 2026 |
| 84 | MetLife Investment Management, LLC | 35,746 | 0 (0.00%) | 0.06% | $1 M | Nov 16, 2026 |
| 85 | Prudential Financial Inc | 35,293 | -132,262 (-78.94%) | 0.05% | $1 M | Nov 16, 2026 |
| 86 | Squarepoint Ops LLC | 33,691 | -134,426 (-79.96%) | 0.05% | $1 M | Nov 9, 2026 |
| 87 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 33,081 | -2,454 (-6.91%) | 0.05% | $1 M | Nov 16, 2026 |
| 88 | Tudor Investment Corp Et Al | 32,176 | +9,658 (+42.89%) | 0.05% | $0 M | Nov 16, 2026 |
| 89 | VANGUARD ASSET MANAGEMENT, Ltd | 31,656 | -481 (-1.50%) | 0.05% | $0 M | Nov 13, 2026 |
| 90 | Russell Investments Group, Ltd. | 31,320 | +2,736 (+9.57%) | 0.05% | $0 M | Nov 6, 2026 |
| 91 | XTX Topco Ltd | 30,390 | -46,575 (-60.51%) | 0.05% | $0 M | Nov 16, 2026 |
| 92 | BNP Paribas Financial Markets | 29,553 | +20,065 (+211.48%) | 0.05% | $0 M | Nov 12, 2026 |
| 93 | Citigroup Inc | 28,341 | -96,068 (-77.22%) | 0.04% | $0 M | Nov 4, 2026 |
| 94 | Legal & General Group Plc | 27,477 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 95 | Aquatic Capital Management LLC | 27,135 | New | 0.04% | $0 M | Nov 16, 2026 |
| 96 | Mercer Global Advisors Inc /adv | 26,930 | +5,008 (+22.84%) | 0.04% | $0 M | Nov 16, 2026 |
| 97 | Millennium Management LLC | 25,633 | -320,599 (-92.60%) | 0.04% | $0 M | Nov 16, 2026 |
| 98 | Panagora Asset Management Inc | 24,396 | 0 (0.00%) | 0.04% | $0 M | Nov 12, 2026 |
| 99 | Jupiter Research Capital (Asia) Ltd | 23,474 | New | 0.04% | $0 M | Nov 16, 2026 |
| 100 | Virtus Investment Advisers, LLC | 23,163 | -720 (-3.01%) | 0.04% | $0 M | Nov 12, 2026 |
Mutual funds holding Cullinan Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 2.38 M | $43 M | 3.7% | 0.40% | +82% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.93 M | $35 M | 3.0% | <0.01% | +4.0% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 1.58 M | $29 M | 2.4% | 0.03% | +20% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price New Horizons Fund, Inc.T. Rowe Price Associates, Inc. | 1.02 M | $19 M | 1.6% | 0.13% | +140% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 621,218 | $11 M | 0.96% | 0.01% | +9.0% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 660,987 | $11 M | 1.0% | 0.03% | +24% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc. | 583,803 | $11 M | 0.90% | 0.09% | −15% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 562,565 | $10 M | 0.87% | 0.07% | +22% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Cap Growth Equity FundT. Rowe Price Associates, Inc. | 559,800 | $10 M | 0.86% | 0.10% | +88% | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 318,933 | $6 M | 0.49% | 0.06% | −1.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 303,486 | $5 M | 0.47% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 Nuveen Quant Small Cap Equity FundTeachers Advisors, LLC | 301,774 | $5 M | 0.46% | 0.12% | −35% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 277,141 | $5 M | 0.43% | 0.03% | +3.6% | May 31, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 266,914 | $4 M | 0.41% | 0.01% | −1.7% | May 31, 2026 |
| 🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc. | 246,130 | $4 M | 0.38% | 0.02% | −1.6% | May 31, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 211,090 | $4 M | 0.33% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 202,566 | $4 M | 0.31% | 0.24% | +49% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 196,482 | $3 M | 0.30% | 0.04% | +0.4% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 188,192 | $3 M | 0.29% | 0.02% | −6.5% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Mid Cap ETFT. Rowe Price Associates, Inc. | 156,443 | $3 M | 0.24% | 0.11% | new | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 170,697 | $3 M | 0.26% | <0.01% | +4.4% | Jul 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 146,560 | $2 M | 0.23% | 0.03% | +25% | Jul 31, 2026 |
| 🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP | 142,879 | $2 M | 0.22% | 0.01% | +53% | Jul 31, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 133,270 | $2 M | 0.21% | 0.08% | +11% | May 31, 2026 |
| 🇺🇸 T. Rowe Price Integrated U.S. Small-Mid Cap Core Equity FundT. Rowe Price Associates, Inc. | 115,618 | $2 M | 0.18% | 0.11% | +100% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 113,081 | $2 M | 0.17% | 0.03% | +38% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 104,413 | $2 M | 0.16% | 0.06% | +122% | Jun 30, 2026 |
| 🇺🇸 iShares U.S. Small-Cap Equity Factor ETFBlackRock Fund Advisors | 115,107 | $2 M | 0.18% | 0.05% | +7.1% | Jul 31, 2026 |
| 🇺🇸 Vanguard U.S. Momentum Factor ETFThe Vanguard Group, Inc. | 114,553 | $2 M | 0.18% | 0.10% | +455% | May 31, 2026 |
| 🇺🇸 Invesco Dorsey Wright SmallCap Momentum ETFInvesco Capital Management LLC | 102,876 | $2 M | 0.16% | 0.41% | new | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 97,554 | $2 M | 0.15% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 93,627 | $2 M | 0.14% | 0.06% | +0.5% | Jul 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 84,571 | $2 M | 0.13% | 0.07% | +26% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 88,087 | $1 M | 0.14% | <0.01% | −0.8% | May 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 76,920 | $1 M | 0.12% | 0.11% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 80,791 | $1 M | 0.12% | 0.27% | +8.0% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 80,186 | $1 M | 0.12% | 0.03% | +23% | Jul 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 72,163 | $1 M | 0.11% | <0.01% | +2.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 78,550 | $1 M | 0.12% | <0.01% | +5.9% | May 31, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 74,579 | $1 M | 0.11% | <0.01% | −33% | Jul 31, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 65,812 | $1 M | 0.10% | 0.03% | +21% | Jun 30, 2026 |
| 🇺🇸 T.Rowe Price Small Cap Growth PortfolioBrighthouse Investment Advisers, LLC | 63,185 | $1 M | 0.10% | 0.10% | +79% | Jun 30, 2026 |
| 🇺🇸 Tema Oncology ETFTema ETFs LLC | 62,826 | $1 M | 0.10% | 0.59% | +33% | May 31, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 54,308 | $1 M | 0.08% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 JPMorgan U.S. Small Company FundJ.P. Morgan Investment Management Inc. | 51,823 | $1 M | 0.08% | 0.08% | −6.7% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Tax Managed Small/Mid Cap FundOLIVE STREET INVESTMENT ADVISERS LLC | 51,795 | $1 M | 0.08% | 0.03% | no change | Jun 30, 2026 |
| 🇺🇸 Transamerica T. Rowe Price Small Cap VPTransamerica Asset Management, Inc. | 46,451 | $1 M | 0.07% | 0.12% | +146% | Jun 30, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 43,000 | $1 M | 0.07% | 0.03% | +18% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc. | 42,900 | $1 M | 0.07% | 0.10% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 2 PortfolioDimensional Fund Advisors LP | 46,694 | $1 M | 0.07% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundNorthern Trust Investments, Inc. | 41,929 | $1 M | 0.06% | 0.11% | new | Jun 30, 2026 |
| 🇺🇸 LVIP Franklin Templeton Multi-Factor SMID Cap Equity FundLincoln Financial Investments Corporation | 40,971 | $1 M | 0.06% | 0.07% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 42,461 | $1 M | 0.07% | 0.05% | +5.2% | May 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 35,850 | $1 M | 0.06% | 0.03% | +48% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 39,408 | $1 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index ETFFidelity Management & Research Company LLC | 37,131 | $1 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 32,552 | $1 M | 0.05% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 32,170 | $1 M | 0.05% | 0.03% | +66% | Jun 30, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 34,598 | $1 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 30,710 | $1 M | 0.05% | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 30,582 | $1 M | 0.05% | 0.03% | +27% | Jun 30, 2026 |
| 🇺🇸 Optimize Strategy Index ETFSound Capital Solutions, LLC | 28,061 | $1 M | 0.04% | 0.18% | −0.3% | Jun 30, 2026 |
| 🇺🇸 U.S. Core Equity 1 PortfolioDimensional Fund Advisors LP | 30,828 | $1 M | 0.05% | <0.01% | +12% | Jul 31, 2026 |
| 🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc. | 30,330 | $0 M | 0.05% | <0.01% | +1.6% | May 31, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 28,892 | $0 M | 0.04% | 0.03% | +24% | Jul 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 28,834 | $0 M | 0.04% | <0.01% | +11% | Jul 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 23,711 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 U.S. Vector Equity PortfolioDimensional Fund Advisors LP | 25,072 | $0 M | 0.04% | <0.01% | +50% | Jul 31, 2026 |
| 🇺🇸 AST PGIM Aggressive Multi-Asset PortfolioAST Investment Services, Inc. | 22,400 | $0 M | 0.03% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 21,069 | $0 M | 0.03% | 0.06% | new | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 20,683 | $0 M | 0.03% | 0.03% | +38% | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 20,264 | $0 M | 0.03% | 0.03% | +10% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 21,532 | $0 M | 0.03% | 0.03% | no change | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 19,400 | $0 M | 0.03% | 0.01% | +7.2% | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 18,921 | $0 M | 0.03% | 0.11% | −14% | Jun 30, 2026 |
| 🇺🇸 AQR Small Cap Multi-Style FundAQR CAPITAL MANAGEMENT, LLC | 18,923 | $0 M | 0.03% | 0.09% | new | Jun 30, 2026 |
| 🇺🇸 MFS Blended Research Small Cap Equity FundMASSACHUSETTS FINANCIAL SERVICES COMPANY | 20,617 | $0 M | 0.03% | 0.10% | new | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 19,730 | $0 M | 0.03% | 0.01% | +8.8% | Jul 31, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 17,375 | $0 M | 0.03% | 0.03% | +30% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 16,625 | $0 M | 0.03% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 23,146 | $0 M | 0.04% | 0.17% | — | Apr 30, 2026 |
| 🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc. | 16,384 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity MSCI Health Care Index ETFFidelity Management & Research Company LLC | 17,979 | $0 M | 0.03% | <0.01% | +22% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 17,018 | $0 M | 0.03% | <0.01% | +127% | Jul 31, 2026 |
| 🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC | 15,200 | $0 M | 0.02% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 16,447 | $0 M | 0.03% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 15,668 | $0 M | 0.02% | 0.10% | new | May 31, 2026 |
| 🇺🇸 Avantis U.S. Equity ETFAmerican Century ETF Trust | 15,101 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 13,570 | $0 M | 0.02% | 0.11% | +40% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 13,415 | $0 M | 0.02% | 0.03% | +24% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 12,361 | $0 M | 0.02% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 12,273 | $0 M | 0.02% | 0.03% | +13% | Jun 30, 2026 |
| 🇺🇸 LVIP JPMorgan Small Cap Core FundLincoln Financial Investments Corporation | 11,564 | $0 M | 0.02% | 0.09% | −5.4% | Jun 30, 2026 |
| 🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC | 10,800 | $0 M | 0.02% | 0.11% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 9,503 | $0 M | 0.01% | 0.03% | +26% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 9,481 | $0 M | 0.01% | 0.04% | +18% | Jun 30, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 10,351 | $0 M | 0.02% | 0.01% | +30% | Jul 31, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 9,227 | $0 M | 0.01% | 0.03% | +42% | Jun 30, 2026 |
| 🇺🇸 iShares Morningstar Small-Cap Value ETFBlackRock Fund Advisors | 10,177 | $0 M | 0.02% | 0.02% | new | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 8,166 | $0 M | 0.01% | 0.03% | +27% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Cullinan Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Jennifer MichaelsonChief Scientific Officer | Option exercise10b5-1 plan | +3,805 | $4.300 | $16 K | 162,649 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Sell10b5-1 plan | -4,000 | $12.36 | $49 K | 158,649 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Option exercise10b5-1 plan | +4,000 | $4.300 | $17 K | 166,844 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Sell10b5-1 plan | -8,000 | $21.57 | $173 K | 158,844 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Option exercise10b5-1 plan | +30,000 | $4.300 | $129 K | 192,844 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Sell10b5-1 plan | -30,000 | $20.26 | $608 K | 162,844 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Option exercise10b5-1 plan | +4,000 | $4.300 | $17 K | 170,844 | Form 4 |
| filed | Jennifer MichaelsonChief Scientific Officer | Sell10b5-1 plan | -8,000 | $17.82 | $143 K | 162,844 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Cullinan Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1 split in the period to
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q4 2020 | Q4 2021 | $6.4M |
| Q3 2020 | Q3 2021 | $0M |
| Q2 2020 | Q2 2021 | $0M |
| Q1 2020 | Q1 2021 | $0.2M |
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Cullinan Therapeutics, Inc. scorecard#
Passes 1 of the 6 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✗Net income higher than five years earlier-$220 M-$220 M in fiscal 2025 against -$52 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$220 MNet income -$220 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-44.0%-44.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities10.2×Current ratio 10.25 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Cullinan Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | — | — | 0−100%— | 19—100% | 0—— | |
| Research and development | 187+31.1%— | 143−3.5%— | 148+61.1%— | 92+59.2%— | 58+33.6%305% | 43—— | |
| General and administrative | 54+0.4%— | 54+27.1%— | 42+5.7%— | 40+37.9%— | 29+70.2%154% | 17—— | |
| Operating expenses | 242+22.7%— | 197+3.3%— | 191+44.3%— | 132+52.1%— | 87+44.0%459% | 60—— | |
| Operating income | −242—— | −197—— | −191−232%— | 145—— | −68—−359% | −60—— | |
| Interest and finance income | 22−25.1%— | 30+37.1%— | 22+227%— | 6.6+1286%— | 0.5−46.3%2.5% | 0.9—— | |
| Other non-operating income (expense) | −0.4—— | −0.2−183%— | 0.2+319%— | 0.1—— | −0.0—−0.0% | −0.0—— | |
| Income before tax | −220—— | −167—— | −169−212%— | 151—— | −67—−356% | — | |
| Income tax | 0−100%— | 0.1—— | −14−134%— | 42—— | 0—0.0% | — | |
| Net income including minority interests | −220—— | −168—— | −155−242%— | 109—— | −67—−356% | −59—— | |
| Minority interests' share of net income | 0—— | −0.2—— | −1.9—— | −2.0—— | −1.9—−10.1% | −7.7—— | |
| Net income attributable to shareholders | −220—— | −167—— | −153−238%— | 111—— | −66—−346% | −52—— | |
| Earnings per share, basic | — | — | -3.69−250%— | 2.46—— | -1.52—— | -2.60—— | |
| Earnings per share, diluted | — | — | -3.69−255%— | 2.38—— | -1.52—— | -2.60—— | |
| Shares, weighted average (basic) | — | — | 42−8.0%— | 45+4.8%— | 43—— | — | |
| Shares, weighted average (diluted) | — | — | 42−10.9%— | 47+8.3%— | 43r43+117%— | 20—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 88+6.4%19.7% | 83−15.7%13.3% | 98−37.0%20.3% | 156+161%27.8% | 60−64.5%13.7% | 168—78.3% | |
| Short-term investments | 290−8.4%64.6% | 316−14.3%50.8% | 369+18.5%76.1% | 311+34.9%55.5% | 231+449%52.8% | 42—19.6% | |
| Other current assets | — | — | 3.9+530%0.8% | 0.6—0.1% | — | — | |
| Current assets | 387−6.7%86.3% | 415−13.6%66.7% | 480+1.2%99.2% | 474+60.0%84.6% | 297+39.7%67.8% | 212—98.9% | |
| Property, plant and equipment | 0.4−38.4%0.1% | 0.7−30.9%0.1% | 1.0−15.8%0.2% | 1.2+1425%0.2% | 0.1−40.8%0.0% | 0.1—0.1% | |
| Right-of-use (leased) assets | 2.6+57.8%0.6% | 1.7−34.4%0.3% | 2.5−38.4%0.5% | 4.1—0.7% | 0—0.0% | — | |
| Long-term investments | 58−71.5%13.0% | 204—32.9% | 0−100%0.0% | 81−42.4%14.4% | 140—32.1% | 0—0.0% | |
| Total assets | 448−27.9%100% | 622+28.4%100% | 484−13.7%100% | 561+28.3%100% | 437+104%100% | 215—100% | |
| Accounts payable | 0.8−50.0%0.2% | 1.7−32.5%0.3% | 2.5−6.3%0.5% | 2.7−16.1%0.5% | 3.2−67.3%0.7% | 9.7—4.5% | |
| Current liabilities | 38+23.1%8.4% | 31+8.9%4.9% | 28+25.1%5.8% | 22+91.5%4.0% | 12−18.0%2.7% | 14—6.7% | |
| Lease liabilities (non-current) | 1.9+124%0.4% | 0.8−60.5%0.1% | 2.2−40.1%0.4% | 3.6—0.6% | 0—0.0% | — | |
| Total liabilities | 40+25.9%8.8% | 31+4.0%5.1% | 30+16.1%6.3% | 26+121%4.6% | 12−17.9%2.7% | 14—6.7% | |
| Retained earnings | −588—−131% | −368—−59.2% | −201—−41.5% | −48—−8.5% | −159—−36.3% | −93—−43.5% | |
| Shareholders' equity | 409−30.8%91.2% | 590+30.1%94.9% | 454−15.2%93.7% | 535+25.9%95.4% | 425+114%97.2% | 199—92.7% | |
| Minority interests | 0—0.0% | 0−100%0.0% | 0.2—0.0% | 0−100%0.0% | 0.4−69.1%0.1% | 1.3—0.6% | |
| Total equity | 409−30.8%91.2% | 590+30.1%94.9% | 454−15.2%93.7% | 535+25.8%95.4% | 425+112%97.3% | 200r200—93.3% | |
| Total liabilities and equity | 448−27.9%100% | 622+28.4%100% | 484−13.7%100% | 561+28.3%100% | 437+104%100% | 215—100% | |
| Shares outstanding | 60+3.0%— | 59+36.4%— | 43−6.3%— | 46+3.4%— | 44+48.5%— | 30r29—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.3+1.6%— | 0.3−1.3%— | 0.3+233%— | 0.1+75.5%— | 0.1−14.5%0.3% | 0.1—— | |
| Share-based compensation | 36−4.7%— | 38+24.3%— | 30+8.9%— | 28+14.7%— | 24+63.5%129% | 15—— | |
| Cash from operating activities | −176—— | −145—— | −134—— | −127—— | −43—−229% | −30—— | |
| Capital expenditure | −0.0—— | 0—— | −0.2—— | −1.1—— | 0—0.0% | −0.0—— | |
| Acquisitions, net of cash acquired | — | — | — | — | — | −1.5—— | |
| Cash from investing activities | 180—— | −136−481%— | 36−85.6%— | 249—— | −334—−1762% | −5.4—— | |
| Shares issued | 0−100%— | 263+584%— | 38—— | 0r6.0−100%— | 3.3−97.7%17.3% | 145—— | |
| Shares bought back | — | — | — | — | — | −6.6—— | |
| Cash from financing activities | 1.1−99.6%— | 266+553%— | 41—— | −26−110%— | 269+91.8%1419% | 140—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 170−8.3%— | 40−4.3%— | 44−27.2%— | 42+1.6%— | 43*+6.1%— | 42+18.2%— | 61+68.3%— | 41+35.3%— | 40*+16.2%— | 36—— | 36—— | 31—— | 35*—— | |
| General and administrative | 49−13.0%— | 12−8.8%— | 13−13.2%— | 12−14.5%— | 12*−15.4%— | 14+2.1%— | 15+7.3%— | 14+9.7%— | 15*+36.8%— | 13—— | 14—— | 12—— | 11*—— | |
| Operating expenses | 219−9.4%— | 53−5.4%— | 57−24.5%— | 54−2.4%— | 55*+0.4%— | 56+13.8%— | 76+51.5%— | 55+27.9%— | 55*+21.0%— | 49—— | 50—— | 43—— | 45*—— | |
| Operating income | −219—— | −53—— | −57—— | −54—— | −55*—— | −56—— | −76—— | −55—— | −55*—— | −49—— | −50—— | −43—— | −45*—— | |
| Interest and finance income | 16−37.7%— | 3.3−35.4%— | 3.6−38.4%— | 4.1−37.7%— | 4.6*−38.6%— | 5.1−39.3%— | 5.9−26.6%— | 6.6+15.6%— | 7.5*+27.0%— | 8.4—— | 8.1—— | 5.7—— | 5.9*—— | |
| Other non-operating income (expense) | −0.3—— | −0.1—— | −0.1—— | −0.1—— | −0.1*−1250%— | −0.1—— | −0.2—— | −0.1—— | 0.0*—— | −0.1—— | −0.1—— | −0.0—— | −0.1*—— | |
| Income before tax | — | — | — | — | — | — | — | — | — | — | — | — | −40*—— | |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | −14*—— | |
| Net income including minority interests | −203—— | −49—— | −54—— | −50—— | −51*—— | −51—— | −70—— | −49—— | −48*—— | −41—— | −42—— | −37—— | −26*—— | |
| Minority interests' share of net income | — | — | — | — | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | −0.2—— | −1.8*—— | |
| Net income attributable to shareholders | — | — | — | — | −51*—— | −51—— | −70—— | −49—— | −48*—— | −41—— | −42—— | −37—— | −24*—— | |
| Earnings per share, basic | — | — | — | — | — | — | — | — | — | -0.69—— | -0.75—— | -0.86—— | — | |
| Earnings per share, diluted | — | — | — | — | — | — | — | — | — | -0.69—— | -0.75—— | -0.86—— | — | |
| Shares, weighted average (basic) | — | — | — | — | — | — | — | — | — | 58—— | 55—— | 43—— | — | |
| Shares, weighted average (diluted) | — | — | — | — | — | — | — | — | — | 58—— | 55—— | 43—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 88—27.4% | 88−14.6%27.4% | 79+8.0%21.6% | 75−2.1%18.6% | 88+6.4%19.7% | 103+1.2%21.3% | 73−36.7%14.0% | 77+3.3%13.2% | 83−15.7%13.3% | 102—15.6% | 115—16.9% | 74—16.5% | 98—20.3% | |
| Short-term investments | 201—62.4% | 201−12.2%62.4% | 256+32.8%70.3% | 277+21.8%68.7% | 290−8.4%64.6% | 229−51.8%47.4% | 193−64.8%37.0% | 227−36.7%39.2% | 316−14.3%50.8% | 476—72.9% | 547—80.4% | 359—79.8% | 369—76.1% | |
| Other current assets | — | — | — | — | — | — | — | — | — | — | — | — | 3.9—0.8% | |
| Current assets | 298—92.4% | 298−12.9%92.4% | 342+23.9%94.0% | 361+13.7%89.7% | 387−6.7%86.3% | 342−42.2%70.7% | 276−59.3%53.0% | 318−28.7%54.8% | 415−13.6%66.7% | 592—90.6% | 678—99.5% | 446—99.2% | 480—99.2% | |
| Property, plant and equipment | 0.2—0.1% | 0.2−57.1%0.1% | 0.3−53.8%0.1% | 0.3−43.7%0.1% | 0.4−38.4%0.1% | 0.5−35.7%0.1% | 0.6−31.9%0.1% | 0.6−33.5%0.1% | 0.7−30.9%0.1% | 0.8—0.1% | 0.8—0.1% | 0.9—0.2% | 1.0—0.2% | |
| Right-of-use (leased) assets | 2.0—0.6% | 2.0+90.8%0.6% | 2.2+89.2%0.6% | 2.4+57.2%0.6% | 2.6+57.8%0.6% | 1.0−48.2%0.2% | 1.2−44.4%0.2% | 1.6−33.6%0.3% | 1.7−34.4%0.3% | 2.0—0.3% | 2.1—0.3% | 2.3—0.5% | 2.5—0.5% | |
| Long-term investments | 22—6.8% | 22−84.4%6.8% | 19−92.2%5.2% | 39−85.2%9.6% | 58−71.5%13.0% | 140+141%28.9% | 242—46.6% | 259—44.7% | 204—32.9% | 58—8.9% | — | — | 0—0.0% | |
| Total assets | 323—100% | 323−33.4%100% | 364−30.1%100% | 403−30.5%100% | 448−27.9%100% | 484−25.9%100% | 520−23.6%100% | 580+29.0%100% | 622+28.4%100% | 653—100% | 681—100% | 449—100% | 484—100% | |
| Accounts payable | 1.1—0.4% | 1.1−34.1%0.4% | 3.7+51.4%1.0% | 2.5−26.2%0.6% | 0.8−50.0%0.2% | 1.7−18.6%0.4% | 2.5+58.3%0.5% | 3.4−8.3%0.6% | 1.7−32.5%0.3% | 2.1—0.3% | 1.6—0.2% | 3.7—0.8% | 2.5—0.5% | |
| Current liabilities | 40—12.4% | 40+22.5%12.4% | 41+44.8%11.2% | 35+28.5%8.7% | 38+23.1%8.4% | 33+35.3%6.8% | 28+19.5%5.4% | 27+24.7%4.7% | 31+8.9%4.9% | 24—3.7% | 23—3.4% | 22—4.9% | 28—5.8% | |
| Lease liabilities (non-current) | 1.1—0.4% | 1.1—0.4% | 1.4+1024%0.4% | 1.7+236%0.4% | 1.9+124%0.4% | 0−100%0.0% | 0.1−91.8%0.0% | 0.5−73.2%0.1% | 0.8−60.5%0.1% | 1.2—0.2% | 1.5—0.2% | 1.8—0.4% | 2.2—0.4% | |
| Total liabilities | 41—12.8% | 41+26.0%12.8% | 42+49.1%11.6% | 37+32.2%9.1% | 40+25.9%8.8% | 33+29.0%6.8% | 28+12.8%5.4% | 28+17.2%4.8% | 31+4.0%5.1% | 25—3.9% | 25—3.7% | 24—5.3% | 30—6.3% | |
| Retained earnings | −741—−230% | −741—−230% | −691—−190% | −638—−158% | −588—−131% | −537—−111% | −487—−93.6% | −417—−71.9% | −368—−59.2% | −321—−49.1% | −280—−41.1% | −238—−53.0% | −201—−41.5% | |
| Shareholders' equity | — | — | — | — | 409−30.8%91.2% | 451−28.1%93.2% | 492−25.0%94.6% | 552+29.6%95.2% | 590+30.1%94.9% | 628—96.1% | 656—96.3% | 426—94.7% | 454—93.7% | |
| Minority interests | — | — | — | — | 0—0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0−100%0.0% | 0—0.0% | 0—0.0% | 0—0.0% | 0.2—0.0% | |
| Total equity | 281—87.2% | 281−37.7%87.2% | 322−34.6%88.4% | 366−33.6%90.9% | 409−30.8%91.2% | 451−28.1%93.2% | 492−25.0%94.6% | 552+29.6%95.2% | 590+30.1%94.9% | 628—96.1% | 656—96.3% | 426—94.7% | 454—93.7% | |
| Total liabilities and equity | 323—100% | 323−33.4%100% | 364−30.1%100% | 403−30.5%100% | 448−27.9%100% | 484−25.9%100% | 520−23.6%100% | 580+29.0%100% | 622+28.4%100% | 653—100% | 681—100% | 449—100% | 484—100% | |
| Shares outstanding | 65—— | 65+9.9%— | 64+8.9%— | 61+4.7%— | 60+3.0%— | 59+1.6%— | 59+2.1%— | 59+36.3%— | 59+36.4%— | 58—— | 58—— | 43—— | 43—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.3−6.1%— | 0.1*−32.9%— | 0.1*+2.6%— | 0.1+3.9%— | 0.1*+2.6%— | 0.1*+3.9%— | 0.1*0.0%— | 0.10.0%— | 0.1*0.0%— | 0.1*—— | 0.1*—— | 0.1—— | 0.1*—— | |
| Share-based compensation | 32−17.2%— | 8.4−11.5%— | 8.4−14.6%— | 7.6−18.8%— | 7.3*−24.1%— | 9.5+0.4%— | 9.9−6.1%— | 9.4+13.9%— | 9.6*+28.1%— | 9.4—— | 11—— | 8.2—— | 7.5*—— | |
| Cash from operating activities | −165—— | −43*—— | −38*—— | −46—— | −38*—— | −37*—— | −58*—— | −43—— | −37*—— | −34*—— | −36*—— | −38—— | −18*—— | |
| Capital expenditure | — | — | — | — | −0.0*—— | — | — | — | 0*—— | 0*—— | 0*—— | 0—— | 0*—— | |
| Cash from investing activities | 147−15.2%— | 52*−23.4%— | 41*−23.8%— | 32−11.9%— | 22*+40.3%— | 67*+239%— | 53*—— | 37+184%— | 16*−69.0%— | 20*—— | −185*—— | 13—— | 51*—— | |
| Shares issued | — | — | — | — | 0*—— | 0*—— | — | — | 0*—— | 0*—— | — | — | 0*—— | |
| Cash from financing activities | 3.3+66.6%— | 1.1*—— | 1.1*+195%— | 0.4—— | 0.7*−54.8%— | 0*−100%— | 0.4*−99.9%— | 0−100%— | 1.6*+538%— | 1.3*—— | 262*—— | 1.1—— | 0.2*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Cullinan Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Nadim Ahmed | $5.1 M | $2.3 M | $2.2 M | $98 |
| 2024Mr. Ahmed | $7.7 M | $8.9 M | $3.8 M | $115 |
| 2023Mr. Ahmed | $4.0 M | −$185 K | $2.3 M | $96590 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Cullinan Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Material agreement 1 · Agreement ended 1 · Shareholder vote 2 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Agreement ended | 8-K | |
| Results announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Shareholder vote | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
H-1B hiring at Cullinan Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $195 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Director, InnovationNatural Sciences Managers | 1 | $195 K |
Where: Cambridge, MA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Cullinan Management, Inc.
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Cullinan Therapeutics, Inc.🇺🇸 | — | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of December 31, 2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Cullinan Therapeutics, Inc.? Verify and update this profile — free
Show Cullinan Therapeutics, Inc.'s ranking on your website Get the badge
The badge updates itself as the ranking changes.